Real-World study tracks breast cancer drug performance outside the lab

NCT ID NCT07243002

Recruiting now Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study is observing 3,000 people with early-stage HR+/HER2- breast cancer who are taking ribociclib or abemaciclib as part of their routine care. Researchers will look at how long patients stay cancer-free, how well they stick to their medication, and their quality of life. The goal is to understand how these drugs work in real-world settings, not just in controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ribociclib and abemaciclib (CDK4/6 inhibitors)
What this could lead to: If successful, this could provide real-world evidence on how well these drugs work and are tolerated outside of clinical trials.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by patient selection and other factors. It does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Novartis Investigative Site
RECRUITING

London, SW3 6JJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.